Abstract:Bile acid (BA) pool homeostasis can be disturbed when cholestasis, and ursodeoxycholic acid (UDCA) treatment is able to rectify the perturbed pool. Efforts were made here to propose a strategy enabling BAs-focused widely quantitative metabolomics and subsequently to lucubrate BA pool fluctuation trajectory in rats after dosing UDCA. A so-called universal metabolome standard (UMS) sample containing numerous natural BAs was constructed by involving various available BAs-enriched matrices. In-depth chemical characterization was conducted for UMS to capture as many BAs as possible. Diverse survey experiments were performed on Qtrap-MS to search BAs, and IT-TOF-MS was deployed to provide high-resolution m/z values for both precursor and fragment ion species. After structural annotation for 120 BAs, in total, online energy-resolved MS was subsequently programmed to pursue superior parameters for certain BAs, particularly BAs bearing two conjugated moieties. UMS was serially diluted to generate calibration sample set, and the regressive calibration curves, 120 ones in total, were responsible for converting each analyte response to quasi-content (1/dilution fold). The validated widely quasi-quantitative program was then applied to profile BA pool shift trajectories against time in UDCA- and vehicle-treated rats. Mild variations were observed for the quantitative pattern of BA pool from vehicle group, whereas UDCA could significantly shape BAs sub-metabolome. Significant increments occurred for the contents of not only the downstream BAs, but some upstream molecules in BA metabolic network. The shift levels of BAs were primarily governed by their distances away from UDCA. Fourteen differential BAs were involved for absolute quantitation to generate the concentration vs. time patterns, and dramatic upgradation occurred for most BAs, consolidating the variations transmitted from large-scale quasi-quantitative metabolomics. Above all, current study revealed the quasi-quantitative details of BA pool fluctuation initiated by UDCA-treatment, and more importantly, provided a promising approach for temporal BAs-targeted metabolomics.

A molecular mechanism of UDCA engagement with GPBAR and subsequent G protein interaction revealed by scattered alanine scanning

Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling

Evidence for the Association Between IgG‐antimitochondrial Antibody and Biochemical Response to Ursodeoxycholic Acid Treatment in Primary Biliary Cholangitis

Ursodeoxycholic Acid Accelerates Bile Acid Enterohepatic Circulation

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

UGT-dependent Regioselective Glucuronidation of Ursodeoxycholic Acid and Obeticholic Acid and Selective Transport of the Consequent Acyl Glucuronides by OATP1B1 and 1B3.

Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα

Ursodeoxycholic Acid Alters Bile Acid and Fatty Acid Profiles in a Mouse Model of Diet-Induced Obesity.

A Multicenter, Randomized, Double-Blind Trial Comparing The Efficacy And Safety Of Tudca And Udca In Chinese Patients With Primary Biliary Cholangitis

Ursodeoxycholic acid: unique properties and clinical applications

Structural basis of bile acid receptor activation and Gs coupling

Clinical Efficacy of Ursodesoxycholic Acid for the Treatment of Primary Biliary Cirrhosis: a Meta-analysis

Widely quasi-quantitative analysis enables temporal bile acids-targeted metabolomics in rat after oral administration of ursodeoxycholic acid

Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Observation on Therapeutic Efficacy of Ursodeoxycholic Acid in Chinese Patients with Primary Biliary Cirrhosis: a 2-Year Follow-Up Study

Structural basis of GPBAR activation and bile acid recognition

Advances in Study of Ursodeoxycholic Acid in the Treatment of Primary Biliary Cirrhosis

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

Biological synthesis of ursodeoxycholic acid

Therapeutic Role of Ursodeoxycholic Acid in Colitis-Associated Cancer Via Gut Microbiota Modulation